This specific mutation, present in ~3% of CRC cases,2 is associated with significantly reduced progression-free survival (PFS) and overall survival (OS) compared to KRAS wild-type tumors.3–5 The convergence of these poor survival outcomes with demonstrated refractoriness to conventional cytotoxic therapies and anti-EGFR regimens underscores an urgent need for innovative therapeutic strategies. The gene discussed is EGFR; the disease is colorectal carcinoma.